A 62-year-old woman presents with tense bullae on flexural surfaces and lower abdomen for 3 weeks. Histopathology shows subepidermal bulla with eosinophil-rich infiltrate. Direct immunofluorescence (DIF) reveals linear IgG and C3 deposits along the basement membrane zone. Indirect immunofluorescence (IIF) on patient's serum shows circulating IgG antibodies against 180 kDa antigen. Which of the following best explains the pathogenic mechanism in this patient?

Explanation

## Clinical Diagnosis This patient has **Bullous Pemphigoid (BP)**, a subepidermal blistering disorder characterized by: - Tense bullae on flexural surfaces (antecubital/popliteal fossae, lower abdomen) - Subepidermal bulla on histology with eosinophil-rich infiltrate - Linear IgG and C3 deposits at the basement membrane zone (BMZ) - Circulating IgG antibodies against 180 kDa antigen (BP180) ## Pathogenic Mechanism **Key Point:** BP180 (collagen XVII) is a transmembrane hemidesmosomal component. Autoantibodies against BP180 activate complement (classical pathway), leading to: 1. C3 cleavage and C5a generation 2. Recruitment and activation of neutrophils and eosinophils at the BMZ 3. Release of proteolytic enzymes (elastase, collagenase) 4. Degradation of anchoring fibrils and hemidesmosomes 5. Subepidermal separation and blister formation **High-Yield:** The 180 kDa antigen is the **extracellular domain of BP180 (NC16A domain)**, the primary target in BP. Antibodies against BP230 (230 kDa) occur in only ~30% of BP cases and are not the dominant pathogenic mechanism. ## Why BP180 and Not BP230? | Feature | BP180 | BP230 | |---------|-------|-------| | **Antigen location** | Transmembrane hemidesmosomal protein | Intracellular hemidesmosomal protein | | **Frequency in BP** | ~90% of cases | ~30% of cases | | **Pathogenic role** | Primary; activates complement directly | Secondary; unclear pathogenic role | | **IIF serology** | Positive in >90% BP | Positive in ~30% BP | | **Clinical correlation** | Strong correlation with disease activity | Weak correlation | **Clinical Pearl:** Patients with anti-BP180 antibodies alone have more active disease; those with both anti-BP180 and anti-BP230 have milder disease. The 180 kDa antigen (NC16A domain) is the immunodominant epitope and the best serological marker for BP diagnosis and disease monitoring. ## Distinction from Other Bullous Disorders This case is NOT: - **Pemphigus vulgaris** (desmoglein 3 antibodies → acantholysis, intraepidermal bulla) - **Pemphigus foliaceus** (desmoglein 1 antibodies → superficial acantholysis) - **Dermatitis herpetiformis** (IgA deposits at dermal-epidermal junction, associated with celiac disease) **Mnemonic:** **BPTZ** = **BP**180 is **T**ransmembrane, **Z**one (BMZ) antibodies → **Complement** activation → **Subepidermal** blister. ## Reference [cite:Robbins 10e Ch 25] — Bullous pemphigoid pathogenesis and immunology.